CDMOs must now offer platform-based manufacturing, simplified tech transfers, AI-driven automation, and robust analytical services. Speed is also critical—traditional 18–24-month timelines are no ...

Researchers in the lab of Hans-Peter Kiem, MD, PhD, at Fred Hutch Cancer Center have devised a method that could one day treat genetic hematologic disorders by correcting how the body makes blood ...

Cell and gene therapies account for 20% of pipeline Parkinson's therapy bemdaneprocel in Phase 3 trial Pharma success urgently needed, says fund manager FRANKFURT, Sept 25 (Reuters) - Bayer's ...

The cell and gene therapy industry has achieved breakthroughs once thought impossible, translating novel concepts into real therapeutic options for patients. The FDA has now approved 43 cell and gene ...

First investigational allogeneic pluripotent stem cell derived therapy pivotal Phase III clinical trial exPDite-2 with bemdaneprocel started Phase II gene therapy trial REGENERATE-PD with AB-1005 ...

The rapid advancement of biomedical technologies has opened the door to curing previously untreatable diseases, offering hope for longer, healthier, and more productive lives. Innovations such as ...

After axing a wide swath of federal research projects and grants, a recent slew of awards offers a glimpse into the kinds of science the second Trump administration wants to back: in vivo cell ...

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, co-founder Patrick Hsu, Ph.D., told Fierce Biotech. “Stylus was founded in a ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...